FRONTIER IP, the intellectual property specialist, has acquired a 21 per cent stake in The Vaccine Group, a University of Plymouth spin-out.

Edinburgh-based Frontier will support the group as it aims to commercialise novel vaccine platforms to control infections such as bovine tuberculosis, and develop a rapid response to pathogens which unpredictably cross the species barrier and post a significant threat to human health.

Frontier boss Neil Crabb said the vaccine platform can become a “critical resource when new diseases emerge.”

Loading article content